Psychiatry for Population Health Pharmacists Fall 2022 Learning Session

Join us for our inaugural Psychiatry for Population Health Pharmacists Learning Session to be held virtually in partnership with the California Rights Med Collaborative. Many patients with persistently poor control of physical conditions, who benefit the most from advanced pharmacist care services such as Comprehensive Medication Management , have comorbid mental health disorders. However, most pharmacists in outpatient settings have limited training and experience in mental health. The goal of the learning session is to advance the skills of pharmacists practicing in community pharmacies, clinics, and other outpatient settings in providing mental health medication management and/or identifying additional services needed by their patients, supporting a “whole person care” approach to managing patients physical and mental health conditions.



Sunday, October 16, 2022 (Virtual on Zoom)

1 pm – 5 pm

To provide pharmacists with the tools necessary to evaluate the status/severity of mental health conditions and/or develop strategies for the management of psychotropic pharmacotherapy.

Pharmacists committed to optimizing medication therapy for patients with mental health conditions.

Learning Objectives

At the completion of this activity, the participant will be able to:

  • Describe the differing presentations of schizophrenia, schizoaffective disorder, and bipolar disorder including typical course of the disease
  • Compare and contrast commonly used antipsychotic medications
  • Select a anti-psychotic formulation (e.g. ODT, LAI) for a patient based upon individual needs or preferences
  • Identify the non-prescriber members of the treatment team and the services/treatment they may provide
  • Determine if antipsychotic therapy is effective
  • List safety monitoring parameters for antipsychotics
  • Develop a plan for monitoring metabolic effects for a person taking an antipsychotic medication
  • Conduct screening for tardive dyskinesia and extrapyramidal side effects
  • Describe common co-morbid disorders including substance use disorders and other general medical conditions in persons with schizophrenia, schizoaffective disorder, or bipolar disorder
  • Identify how co-morbidities may impact antipsychotic effectiveness and safety
  • Describe reasons why persons are nonadherent to antipsychotic mediation
  • Apply techniques for establishing rapport with persons with serious mental illness to build a therapeutic alliance
  • Use shared decision making and motivational interviewing skills to increase adherence
  • Recognize the information required to make a strong recommendation pertaining to an antipsychotic
  • Describe other recommendations that can be made to assist in increasing treatment adherence

This course meets the CE requirements needed to renew the Advance Practice Pharmacist license in California.

For CE related questions contact the USC Mann School Office of Continuing Professional Development at